- Home
- CUBI vs RCKT Comparison
CUBI vs RCKT Comparison
Compare CUBI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- RCKT
- Stock Information
- Founded
- CUBI 1994
- RCKT 1999
- Country
- CUBI United States
- RCKT United States
- Employees
- CUBI N/A
- RCKT N/A
- Industry
- CUBI Major Banks
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- RCKT Health Care
- Exchange
- CUBI Nasdaq
- RCKT Nasdaq
- Market Cap
- CUBI 1.7B
- RCKT 264.0M
- IPO Year
- CUBI 2012
- RCKT N/A
- Fundamental
- Price
- CUBI $63.96
- RCKT $3.00
- Analyst Decision
- CUBI Buy
- RCKT Buy
- Analyst Count
- CUBI 9
- RCKT 13
- Target Price
- CUBI $67.38
- RCKT $18.50
- AVG Volume (30 Days)
- CUBI 382.7K
- RCKT 3.8M
- Earning Date
- CUBI 07-24-2025
- RCKT 08-04-2025
- Dividend Yield
- CUBI N/A
- RCKT N/A
- EPS Growth
- CUBI N/A
- RCKT N/A
- EPS
- CUBI 3.98
- RCKT N/A
- Revenue
- CUBI $591,500,000.00
- RCKT N/A
- Revenue This Year
- CUBI $12.60
- RCKT N/A
- Revenue Next Year
- CUBI $10.57
- RCKT N/A
- P/E Ratio
- CUBI $15.93
- RCKT N/A
- Revenue Growth
- CUBI N/A
- RCKT N/A
- 52 Week Low
- CUBI $40.75
- RCKT $2.19
- 52 Week High
- CUBI $68.49
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- CUBI 69.29
- RCKT 45.55
- Support Level
- CUBI $61.35
- RCKT $2.76
- Resistance Level
- CUBI $67.04
- RCKT $3.24
- Average True Range (ATR)
- CUBI 2.06
- RCKT 0.19
- MACD
- CUBI 0.26
- RCKT 0.17
- Stochastic Oscillator
- CUBI 68.04
- RCKT 74.85
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.